KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Net Margin (2009 - 2026)

Bristol Myers Squibb (BMY) reported Net Margin of 23.32% for Q1 2026, up 134.0% year-over-year from 9.96% in Q1 2025, and up 168.44% on a QoQ basis from 8.69% in Q4 2025.

Bristol Myers Squibb (BMY) has 18 years of Net Margin data on file, last reported at 23.32% in Q1 2026.

  • Quarterly Net Margin rose 134.0% year-over-year to 23.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.0% (up 382.0% YoY) and the FY2025 annual result came in at 14.64%, up 3314.0% from the prior year.
  • Net Margin rose to 23.32% in Q1 2026 per BMY's latest filing, from 8.69% in the prior quarter.
  • Across five years, Net Margin topped out at 23.32% in Q1 2026 and bottomed at 100.36% in Q1 2024.
  • The 5-year median for Net Margin is 14.33% (2022), against an average of 7.77%.
  • The widest annual swing landed in 2024, when Net Margin slumped 12036 bps; it then soared 12234 bps in 2025.
  • Tracing BMY's Net Margin over 5 years: stood at 17.75% in 2022, then fell by 16 bps to 14.87% in 2023, then plunged by 96 bps to 0.62% in 2024, then jumped by 1311 bps to 8.69% in 2025, then jumped by 168 bps to 23.32% in 2026.
  • Per Business Quant, the three latest BMY Net Margin figures stand at 23.32% (Q1 2026), 8.69% (Q4 2025), and 17.96% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 37.36%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 21.76%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 4.65%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -25.84%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 21.11%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 29.04%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -0.56%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 23.32%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 23.32%
Dec 31, 2025 8.69%
Sep 30, 2025 17.96%
Jun 30, 2025 10.70%
Mar 31, 2025 21.98%
Dec 31, 2024 0.62%
Sep 30, 2024 9.73%
Jun 30, 2024 13.36%
Mar 31, 2024 -100.36%
Dec 31, 2023 14.87%
Sep 30, 2023 17.64%
Jun 30, 2023 18.50%
Mar 31, 2023 20.00%
Dec 31, 2022 17.75%
Sep 30, 2022 14.33%
Jun 30, 2022 12.02%
Mar 31, 2022 11.01%
Dec 31, 2021 19.79%
Sep 30, 2021 12.74%
Jun 30, 2021 8.50%
Mar 31, 2021 17.71%
Dec 31, 2020 -91.14%
Sep 30, 2020 17.13%
Jun 30, 2020 -1.44%
Mar 31, 2020 -7.72%
Dec 31, 2019 -14.60%
Sep 30, 2019 20.98%
Jun 30, 2019 21.31%
Mar 31, 2019 27.30%
Dec 31, 2018 17.78%
Sep 30, 2018 31.66%
Jun 30, 2018 4.93%
Mar 31, 2018 26.61%
Dec 31, 2017 -44.69%
Sep 30, 2017 13.80%
Jun 30, 2017 15.55%
Mar 31, 2017 28.55%
Dec 31, 2016 13.89%
Sep 30, 2016 21.27%
Jun 30, 2016 21.10%
Mar 31, 2016 23.71%
Dec 31, 2015 -8.07%
Sep 30, 2015 13.17%
Jun 30, 2015 -6.68%
Mar 31, 2015 26.13%
Dec 31, 2014 -2.44%
Sep 30, 2014 17.19%
Jun 30, 2014 7.25%
Mar 31, 2014 23.04%
Dec 31, 2013 14.70%
Sep 30, 2013 17.32%
Jun 30, 2013 13.04%
Mar 31, 2013 15.22%
Dec 31, 2012 21.69%
Sep 30, 2012 -19.08%
Jun 30, 2012 24.62%
Mar 31, 2012 28.22%
Dec 31, 2011 24.20%
Sep 30, 2011 25.35%
Jun 30, 2011 24.05%
Mar 31, 2011 27.28%
Dec 31, 2010 -25.85%
Sep 30, 2010 27.14%
Jun 30, 2010 19.38%
Mar 31, 2010 22.90%
Dec 31, 2009 143.35%
Sep 30, 2009 1.90%
Jun 30, 2009 18.76%
Mar 31, 2009 0.02%